methyl 2-(5-fluoro-2-methyl-1H-indol-3-yl)acetate | 1412449-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 2-(5-fluoro-2-methyl-1H-indol-3-yl)acetate
• CAS: 1412449-30-9
• 化学式: C₁₂H₁₂FNO₂
• mdl: MFCD08275137
• 分子量: 221.231
• InChiKey: CFBDIKDOCFJHKG-UHFFFAOYSA-N

物化性质

• 沸点：
  357.3±37.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(5-fluoro-2-methyl-1H-indol-3-yl)acetate 在 trimethyl-tin hydroxide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 反应 0.92h， 生成 2-(5-methoxy-1-propionyl-1H-indol-3-yl)acetic acid
  参考文献：
  名称：

  Straightforward protocol for the efficient synthesis of varied N1-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up

  摘要：

  A library of approximately 40 N-1-acylated (aza)indole alkanoic esters and acids was prepared employing a microwave-assisted approach. The optimized synthetic route allows for parallel synthesis, variation of the indole substitution pattern, and high overall yield. Additionally, the procedure has been scaled up to yield multi-gram amounts of preferred indole compounds, e.g.: 2'-des-methyl indomethacin 2. The reported compounds were designed as biomedical tools for primary and secondary in vitro and in vivo studies at relevant molecular targets. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.08.044
• 作为产物：
  描述：

  乙酰丙酸甲酯 、 4-氟苯肼盐酸盐 在 硫酸 作用下， 以 甲醇 为溶剂， 反应 0.17h， 以59%的产率得到methyl 2-(5-fluoro-2-methyl-1H-indol-3-yl)acetate
  参考文献：
  名称：

  Straightforward protocol for the efficient synthesis of varied N1-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up

  摘要：

  A library of approximately 40 N-1-acylated (aza)indole alkanoic esters and acids was prepared employing a microwave-assisted approach. The optimized synthetic route allows for parallel synthesis, variation of the indole substitution pattern, and high overall yield. Additionally, the procedure has been scaled up to yield multi-gram amounts of preferred indole compounds, e.g.: 2'-des-methyl indomethacin 2. The reported compounds were designed as biomedical tools for primary and secondary in vitro and in vivo studies at relevant molecular targets. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2012.08.044

文献信息

• [EN] DIMERIC IAP INHIBITORS<br/>[FR] INHIBITEURS IAP DIMÉRIQUES
  申请人：NOVARTIS AG

  公开号：WO2012080271A1

  公开（公告）日：2012-06-21

  The present invention provides compounds of formula M-L-M' (where M and M' are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. (I)

  本发明提供了公式M-L-M'的化合物（其中M和M'分别独立地是公式（I）的单体基团，L是连接基团）。已发现二聚化合物在促进快速分裂细胞凋亡方面具有有效性。（I）
• [EN] COMPOUNDS FOR THE TREATMENT OF HIV<br/>[FR] COMPOSÉS POUR TRAITER LE VIH
  申请人：GILEAD SCIENCES INC

  公开号：WO2013006738A1

  公开（公告）日：2013-01-10

  The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.

  本发明提供了如下式（I）的化合物或其盐，还提供了包含如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，用于制备如下式（I）化合物的中间体以及治疗Retroviridae病毒感染的治疗方法，包括由HIV病毒引起的感染。
• [EN] INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER<br/>[FR] ANALOGUES DE L'INDOMÉTACINE DESTINÉS AU TRAITEMENT DU CANCER DE LA PROSTATE RÉSISTANT À LA CASTRATION
  申请人：UNIV VANDERBILT

  公开号：WO2013059245A1

  公开（公告）日：2013-04-25

  Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.

  提供了用于抑制醛酮还原酶家族1成员C3（AKR1 C3）多肽的生物活性的组合物。在某些实施例中，这些组合物是吲哚美酸衍生物，是AKR1 C3特异性抑制剂。还提供了生产所述吲哚美酸衍生物的方法，这些衍生物基本缺乏环氧合酶抑制活性，但具有AKR1C3抑制活性，以及抑制AKR1C3多肽生物活性的方法，以及治疗受试者前列腺肿瘤的方法。
• Indole-3-sulphur derivaties
  申请人：Bonnert Roger

  公开号：US20060111426A1

  公开（公告）日：2006-05-25

  The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. (I)

  本发明涉及用作治疗呼吸系统疾病的药物化合物的取代吲哚。 (I)
• Indole-3-Sulphur Derivatives
  申请人：Bonnert Roger

  公开号：US20100197756A1

  公开（公告）日：2010-08-05

  The present invention relates to substituted indoles useful as pharmaceutical compounds for treating respiratory disorders. (I)

  本发明涉及取代吲哚，其作为治疗呼吸系统疾病的药物化合物有用。(I)